Evaluation of Immunotherapy in the Treatment of Melanoma

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

“…The current phase III Theratope ® and hormone therapy breast cancer trial demonstrated a survival beneWt in patients who could mount an adequate antibody immune response to STn [26]. CancerVax which makes Canv-axin™, a whole-cell vaccine prepared from three allogenic melanoma cell lines, is another well known cancer vaccine being studied for metatstatic melanoma that has shown promise in phase III trials (therapeutic vaccine) [27]. Overall both of these trials were negative, but subset analysis has shown that patients who immunologically responded to the respective vaccines had improved outcomes.…”